Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Editas Medicine, Inc.”

20 pharma patents match "Editas Medicine, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 20
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 20 pharmaceutical patents matching "Editas Medicine, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

20 results for “Editas Medicine, Inc.” · 30,257 patents in full index Clear search

  1. US 12359223

    Systems and methods for modulating chromosomal rearrangements

    Editas Medicine, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  2. US 12331328

    CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

    Editas Medicine, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  3. US 12325854

    Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

    Editas Medicine, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  4. US 12201699

    Compositions and methods for promoting homology directed repair

    Editas Medicine, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  5. US 12031132

    Systems and methods for the treatment of hemoglobinopathies

    Editas Medicine, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  6. US 11963982

    CRISPR/RNA-guided nuclease systems and methods

    Editas Medicine, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  7. US 11952408

    HPV-specific binding molecules

    Editas Medicine, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  8. US 11911415

    CRISPR/Cas-related methods and compositions for improving transplantation

    Editas Medicine, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  9. US 11851690

    Systems and methods for the treatment of hemoglobinopathies

    Editas Medicine, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  10. US 11834649

    CRISPR/CAS-related methods and compositions for treating herpes simplex virus

    Editas Medicine, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  11. US 11806408

    Methods and compositions for treating cone-rod retinal dystrophy

    Editas Medicine, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  12. US 11667911

    Use of exonucleases to improve CRISPR/CAS-mediated genome editing

    Editas Medicine, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted
  13. US 11597924

    Genome editing systems comprising repair-modulating enzyme molecules and methods of their use

    Editas Medicine, Inc. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  14. US 11566263

    Compositions and methods for treating CEP290 associated disease

    Editas Medicine, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  15. US 11390884

    Optimized CRISPR/cas9 systems and methods for gene editing in stem cells

    Editas Medicine, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  16. US 11390861

    CRISPR/cas-related methods and compositions for treating herpes simplex virus

    Editas Medicine, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  17. US 11242525

    CRISPR/CAS-related methods and compositions for treating sickle cell disease

    Editas Medicine, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  18. US 11141493

    Compositions and methods for treating CEP290-associated disease

    Editas Medicine, Inc. · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  19. US 11028388

    CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa

    Editas Medicine, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  20. US 11001844

    CRISPR/Cas-related methods and compositions for treating herpes simplex virus

    Editas Medicine, Inc. · Granted May 11, 2021 · Expires May 6, 2041

    granted